- Home
- FTI vs RVMD Comparison
FTI vs RVMD Comparison
Compare FTI & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTI | RVMD |
|---|---|---|
| Founded | 1884 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 15.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FTI | RVMD |
|---|---|---|
| Price | $44.70 | $80.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 17 |
| Target Price | $48.00 | ★ $77.47 |
| AVG Volume (30 Days) | ★ 2.9M | 2.4M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | ★ 59.09 | N/A |
| EPS | ★ 2.28 | N/A |
| Revenue | ★ $9,803,000,000.00 | N/A |
| Revenue This Year | $10.34 | N/A |
| Revenue Next Year | $7.23 | $714.50 |
| P/E Ratio | $19.58 | ★ N/A |
| Revenue Growth | ★ 11.44 | N/A |
| 52 Week Low | $22.12 | $29.17 |
| 52 Week High | $47.33 | $81.97 |
Technical Indicators
Market Signals| Indicator | FTI | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 67.25 |
| Support Level | $43.34 | $74.20 |
| Resistance Level | $45.84 | $81.97 |
| Average True Range (ATR) | 1.11 | 2.50 |
| MACD | -0.27 | -0.44 |
| Stochastic Oscillator | 39.52 | 84.78 |
Price Performance
Historical ComparisonAbout FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.